






































































































































































































































































  co                               O 5 10 15 20 25   O 3 6 9 12 15          Time (min) Time (min)
Fig. 1-3. Contribution of bovine erythrocyte in the perfusate to the improvement
of the renal functions which can be estimated from the reabsorption ratio of
glucose (closed symbol) and water (open symbol). The renal functions in the presence
(panel A) and the absence (panel B) of the erythrocyte were measured in the respective
studies. Three experiments vvere carried out in panel A and panel B, respectively. The
data of glucose and water reabsorption from same experiment were represented with the
same shape,
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Structure of the compounds used in this study.
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Fig. 1-5. Typical outflow profiles of the ionized model compounds,
tetraethylammonium (panel A and B) and p-aminohippurate (panel C and D).
They were dissolved in the injection solution at the concentration of lmM and O.lmM,
respectively. The venous outflow profiles of theirs were indicated in panel A and C, and
the urinary profiles were in B and D. The profile of EB-albumin, which was used as
intravascular marker, was represented by ････. This compound does not appear in the
urine. The profile of the extracellular space and glomerular filtration marker, inulin was
shown with O. Extracted by renal epithelia from the perfusate, the profile of the model
compound, which was indicated by e, was the smallest in the venous profiles. Please note
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32.21 35.42±4.35 68.05 89.30
50.18 38.74j:10.21 26.08 8.63
4.42 2.27j:0.56 2.30 1.56








38.72± 1.77 52.68 ±7.09 84.70±0.56****
49.79±9.08 37.94 ±7.26 13.ll±1.15*
1.61±0.07 2.40 ±0.15* 2.19±0.05*
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Table 2-3 Parameters confirrning the experimental conditions in which the
effects of urine pH on the renal handling of the typical ionized compounds were
investigated. There are no significant differences from the control, except the value of
urine pH. Glomeru1ar fi1tration rate (GFR) was estimated from the creatinine clearance,




  Recovery Ratio (%)
     Plasma
     Urine
  Distribution volume (mL)
95.86 ± O.17
 3.90 ± O.27
 1.08 ± O.09
95.64 ± O.93
14.12 ± O.91
 1.04 ± O.10
95.04 ± 1.05
 4.75 ± 1.04






   6.4
O.31 ± O.07
4.14 ± O.19
    7.1*
O.38 ± O.07
4.03 ± O.25
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Fig. 2-5. Typical cumulative excretien profile of tetraethylammonium under the
conditions in normal urine pH (panel A), urine alkalinization (panel B), and
urine acidification (panel C). The exeretion of tetraethylammonium, whose profile was
indicated by e, was decreased in urine alkalinization. On the contrary, the excretion of
inulin (O) was not affected under any conditions.

















































































































Fig. 2-6. Effects of the alteration of urine pH on the renal handling of
tetraethylammonium and p-aminohippurate. The conditions where the values of urine
pH were normal, increased and decreased were indicated as control, up and down, respectively.
These experiments were carried out under the steady state condition in which the drug was
dissolved in the pemhsate and the injection solution at the concentration of O.ImM.





































































































































































































































































































Table 2-4 Moment pararneters on the renal handling of tetraethylammQnium (TEA) and
p-aminohippurate (PAH) in the perfused kidney isolated from uranyl-nitrate induced acute
renal failure rat were shown, respectively. Parameters confirming the experimental conditions in
which the renal handling of these typical ionized compounds were also indicated. The physiological
condition of the kidney from those rats being often unstable, some group have no data. In addition to this,
not every item can has been analyzed statistically. Glomerular fi1tration rate and plasma flow rate were
abbreviated as GFR and PFR, respectively.


















































































































































































































































































































































































Table 3-1 Recovery ratio and moment parameters of [3H]tobramycin in the
contro1 experiments. Radiolabeled tobramycin and the marker compound inulin were
dissolved in the iniection solution at the concentration of 7.4pM and ca. 60mg/L, respectively.
Then a 50pL of the solution was administrated into the renal artery. Glomerular fi1tration
rate and plasma flow rate were abbreviated as GFR and PFR, respectiyely.
Drug Recovery (%)
        Plasma
        Urine
Inulin Recovery (%)
        Plasma





































  O5 10 15 20 25 30 O 5 10             Time (sec) Time (min)
Fig. 3-2. Typical venous (panel A) and urinary (panel B) outflow profiles of
[3H]tobramycin (e) and [i`Clinulin (O) obtained in the control study in which
the concentration of tobramycin in the injection solution was 7.4pM. In this
experiment, the luminal uptake of tobramycin was 31%. The moment parameters, MTTv
and rmu of tobramycin were 7.7 sec and 3.9 min, respectively, and those of inulin were



























































































































































   O5 10 15 20 25 30 O 5 10             Time (sec) Time (min)
Fig. 3-5. Typical venous (panel A) and urinary (panel B) outflow profiles of
[3H]tobramycin (e) and ['`C]inulin (O) obtained in a dose-dependent experiment
in which tobramycin was dissolved in the injection solution at the concentration
of 100mM. In this experiment, the luminal uptake of tobramycin was 3%. The values of
MTTv and M'I'ru of tobramycin were 7.9 sec and 4 6 min, respectively, and those of inuhn
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     o           Control O.lmM lmM 10mM 100mM
Fig. 3-6. Dose-dependent decrease of the luminal uptake of tobramycin. The
values corrected (1ight gray column) and not corrected (dark column) by the protein binding
ratio were shown, respectively. The protem binding ratio of tobramycin were 19.1% at the






























































































































Table 3-4 Parameters representing the renal handling of [i`C]isepamicin and
l3H]arbekacin. Isepamicin and arbekacin was dissolved in the injection solution at the
concentration of O.lmM and 10mM, respectively. This difference was due to the specific






 1.05 ± O.02
 1.12 ± O.03
24.2 ± 2.9
 1.25 ± O.09


































o 5 10Time (min) 15
Fig. 3-9. Typical venous (panel A) and urinary (panel B) outflow profiles of
['`C]isepamicin (e) and [3H]inulin (O) obtained in the control study. The
concentration of isepamicin in the injection solution was O.lmM. This concentration was
determined from the specific activity ofits radiolabeled compound. In this experiment, the
luminal uptake of isepamicin was 31%. The values of MTTv and M'I'I'u of tobramycin
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25 30 o 5 10Time (min) 15
Fig. 3-10. Typical venous (panel A) and urinary (panel B) outflow profiles of
[3H]arbekacin (e) and ['`C]inulin (O) obtained in the contro1 study where arbekacin
was dissolved in the injeetion solution at the concentration of 10mM. This
concentration was determined from the specific activity ofits radiolabeled compound. In
this experiment, the luminal uptake of arbekacin was 26%. The values of MTTv and
MTTu of arbekacin were 7.1 sec and 3.2 min, respectively. Since those of inulin were 5.7
sec and 2.8 min, rmu Ratio was 1.1.
co
35
























































































































































































































































































































































§ 1.0 0c:: O.
',::l 0
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Time (sec) Time (min)
Fig. 3-14. Typical venous (panel A) and urinary (panel B) outflow profiles of
[~ltobramycin(e) and [14Clinulin (0). These profiles were given in the steady-state experiment
in which lysozyme was dissolved in the perfusate at the concentration of 1001lM, and a 50llL of
the injection solution of eH]tobramycin (7.4IlM) was administered in the same way described
previously. The MTTu Ratio was increased to 2.2 ± 0.1 from the control value 1.2 ± 0.0. There






























1.4 1.6 1.8 2.0 2.2 2.4
MTTu Ratio
Fig. 3-15. Relationship between the luminal uptake of eHltobramycin and its MTTu
Ratio was shown, figure 3-7 being overlaid. The data obtained from the steady-state
experiments in which lysozyme was dissolved in the perfusate at the concentration of 1, 10, and
lOOIlM were indicated by 0,.6, and D, respectively. To avoid the jumble, all data from the
inhibitory study were indicated by the same symbol V. See also the legend of figure 3-7.
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